Physician profile
Stuart Handelsman
NPI 1063444883
$3,594.89
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,722 · 2020: $1,155 · 2021: $718.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $557.67 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $517.94 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $319.09 | 2019-2021 | |
| Akebia Therapeutics INC | $312.17 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $259.74 | 2020-2021 | |
| Nuwellis, INC. | $255.21 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $225.14 | 2019-2021 | |
| Amgen INC. | $200.24 | 2019-2021 | |
| Horizon Therapeutics Plc | $184.89 | 2019-2021 | |
| Glaxosmithkline, LLC. | $125.56 | 2020-2021 | |
| Daiichi Sankyo INC. | $115.48 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $89.70 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $88.28 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $76.64 | 2019 | |
| Mallinckrodt Enterprises LLC | $75.25 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $66.36 | 2019-2021 | |
| Travere Therapeutics, INC. | $36.52 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $26.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.37 | 2021 | |
| Genzyme Corporation | $19.45 | 2019 | |
| Genentech USA, INC. | $18.97 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$677.92 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Handelsman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.